Vaccine platforms that facilitate vaccine introduction and access in low- and middle-income countries (LMICs) are preferred when developing next-generation influenza vaccines, and research should be prioritized for the novel mRNA and viral vectored vaccine platforms that were successful during the COVID-19 pandemic.
This is the advice of the World Health Organization in its revised guide on the development of next-generation flu vaccines,...






